Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

Abstract excerpt

Acute myeloid leukaemia (AML) is the most common and aggressive form of acute leukaemia in adults. The most common driver mutations in AML are activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, occurring in approximately one third of cases [ 1 ]. Internal tandem duplication (FLT3-ITD) mutations in the FLT3 juxtamembrane domain are the most common (~25%), and are associated with genomic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Cancer Genomics and Diagnostics
• Share to Epigenetics and DNA Methylation